Belite Bio (BLTE) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.21B and a free-cash-flow yield of -0.7%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 3.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Rising · +39.7% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-22.9%
How far the last close sits under the highest price of the past five years.
Market cap
$6.21B
Trailing P/E
—
Price / book
8.0
Price / sales
—
FCF yield
-0.7%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
-1.2
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
BLTE earnings
Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.77).
Beat the EPS estimate in 1 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 13, 2026
-$0.70
-$0.78
+10.3%
$0
Q1 2026
May 20, 2026
-$0.68
-$0.64
-6.2%
$0
Q4 2025
Mar 2, 2026
-$0.70
-$0.54
-29.6%
$0
Q3 2025
Nov 10, 2025
-$0.65
-$0.49
-32.6%
$0
BLTE analyst price target
Median target $217.00 from 9 analysts, ranging $185.00 – $303.00.
Nama's AI scorecard currently rates Belite Bio Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does BLTE report earnings?
Belite Bio's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.77.
What is the BLTE price target?
The median analyst price target from 9 analysts is $217.00, with a range of $185.00 – $303.00.
Is BLTE Shariah compliant?
Nama's AAOIFI-style screen reads Belite Bio as Can't Tell. A figure the screen needs is missing, so it can't tell.